Good MorningU.S. stocks leaned lower Wednesday after the Fed held rates steady at Kevin Warsh’s first meeting as chair. The tension was rates versus growth, as a more hawkish policy signal weighed on valuation-sensitive stocks while AI and infrastructure names still found selective support.
The Fed path was the key risk driver. Investors looked past the unchanged rate decision and focused on the possibility of tighter policy later, favoring earnings quality and balance-sheet durability over long-duration growth. That kept pressure on megacap tech, including Amazon, while limiting enthusiasm for crowded trades that need strong growth to justify premium valuations.
SpaceX stayed central after its IPO rally pushed its valuation past Amazon, reinforcing demand for scarce growth stories. Its addition to a Schwab large-cap value ETF also stood out because the holding clashed with the fund’s value label. CoreWeave climbed ahead of Nasdaq-100 inclusion, adding index-demand support to the AI infrastructure theme. AT&T slipped after CFO Pascal Desroches announced his retirement, while Robinhood rose as layoffs and analyst support fed the cost-discipline story. Traders are watching Fed speakers, AI-CapEx updates, and crypto ETF flows. Featured: Buffett's Final Warning: "The Dollar Is Going to Hell" (Ad) 
|
Communication Services | |
Despite markets hitting all-time highs, Americans are still quite pessimistic about the state of the economy. The University of Michigan Index of Consumer Sentiment, one of the most commonly cited surveys, reached a record low of 44.8 in May. Despite a slight rebound in June, sentiment indices sugg... Read the Full Story |
|
From Our Partners | | Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up.
One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing.
See the real reason this conflict may never fully end. | | Uncover the real reason Trump may never end this war |
|
Technology | |
There's nothing quite like the headline "insiders dump billions" to get investors reaching for the sell button. Shares of CoreWeave Inc (NASDAQ: CRWV) have been doing the opposite of selling off. The stock recently traded above $120 after a sharp rally, extending its year-to-date gain of over 65%. ... Read the Full Story |
|
Materials | |
Among the various corners of the stock market, few have attracted as much attention as rare-earth element companies. This comes as the global economy looks to loosen China’s grip on this market by investing in non-Chinese supply chains.
Notably, the U.S. government has extended, or could soon exte... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Communication Services | |
Amid the boom in artificial intelligence spending, one key factor has separated Meta Platforms (NASDAQ: META) from the other Magnificent Seven hyperscalers: cloud computing. Microsoft (NASDAQ: MSFT), Amazon.com (NASDAQ: AMZN), and Alphabet (NASDAQ: GOOGL) all have massive cloud computing businesses... Read the Full Story |
|
Industrials | |
Insider sales are hitting two massive stocks in industrials and retail, as well as a small-cap chip stock. Across these names, insiders are sending bearish signals, but their severity differs meaningfully. For perhaps the most widely recognized name on this list, GE Vernova (NYSE: GEV), two insider... Read the Full Story |
|
From Our Partners | | A little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.25 g/t.
After roughly 21,000 metres of drilling, the company is closing in on its first-ever mineral resource estimate, expected in Q3 or Q4 2026.
That estimate could offer the market its first real look at the scale of this emerging gold system. | | See what could be next for this US gold explorer |
|
Consumer Discretionary | |
Shares of Amazon.com Inc (NASDAQ: AMZN) are trading under $250 this week, down from nearly $275 at the end of last month.
The stock has been buffeted by a combination of AI CapEx concerns, a high-profile rocket explosion, and a broader risk-off mood that's weighed on even the strongest names in te... Read the Full Story |
|
Industrials | |
Crude oil prices have fallen sharply following the June 14-15 announcement that the United States and Iran have reached a framework agreement to end their conflict. The deal, which is in the form of a Memorandum of Understanding (MOU), is expected to be formally signed on June 19 in Switzerland.
Th... Read the Full Story |
|
Energy | |
Markets rarely telegraph structural shifts, but when a massive geopolitical risk premium evaporates overnight, the rerating is always violent. The unexpected diplomatic breakthrough between the United States and Iran has effectively broken the back of the crude rally.
The tentative diplomatic frame... Read the Full Story |
|
Technology | |
Strategic pivots rarely happen without a massive catalyst forcing the issue. For Microsoft (NASDAQ: MSFT), that catalyst may be buried deep in the razor-thin margins of Microsoft's interactive entertainment division. A recent internal memo from Xbox Chief Executive Officer Asha Sharma revealed Micr... Read the Full Story |
|
Consumer Discretionary | |
Dave & Buster’s (NASDAQ: PLAY) price action is not inspiring for bulls. The stock has trended lower for over two years and could continue to decline. The Q1 earnings release failed to meet expectations, setting the stage for new lows.
The caveat is that PLAY stock is already trading at historic... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. | Should I Buy Johnson & Johnson Stock? JNJ Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Johnson & Johnson was last updated on Monday, September 14, 2026 at 6:04 PM.
Johnson & Johnson Bull Case -
Johnson & Johnson is currently trading at $266.81, which is below the consensus price target of $272.82, suggesting potential upside as analysts maintain a Moderate Buy rating based on recent performance.
-
The company recently reported that its RYBREVANT (amivantamab) plus chemotherapy regimen achieved a median overall survival of 34.3 months in EGFR exon 20 insertion mutation-positive non-small cell lung cancer, marking the longest reported survival in this patient population and strengthening its oncology portfolio.
-
Johnson & Johnson has raised its 2026 outlook to 6.5% adjusted operational sales growth and 7.3% adjusted earnings-per-share growth, with total revenue expected to exceed $100 billion for the first time, driven by strong performance in the first two quarters of the year.
-
Executives have indicated a clear line of sight to double-digit growth by the end of the decade, supported by a robust pipeline including 12 molecules in Phase III development and recent acquisitions like Halda Therapeutics and Firefly Bio that expand capabilities in oncology and immunology.
-
The stock offers a dividend yield of 2.02%, providing income stability for investors, while the company’s low beta of 0.24 indicates lower volatility compared to the broader market, making it a defensive holding in uncertain economic conditions.
Johnson & Johnson Bear Case -
Johnson & Johnson’s experimental depression drug, developed with Contineum Therapeutics, failed to meet the main goal of a mid-stage study, representing a setback in the company’s neuroscience pipeline and potentially delaying expected growth in that therapeutic area.
-
The company faces increasing biosimilar competition for its STELARA franchise, which could erode market share and revenue in the immunology segment, although management claims to be on track to grow through this transition.
-
Recent insider activity shows a trend of selling, with multiple executives including Timothy Schmid, Jennifer L Taubert, and Elizabeth Forminard selling significant blocks of shares in the second quarter of 2026, which may signal reduced confidence in near-term stock appreciation.
-
Johnson & Johnson is in talks to sell its DePuy Synthes orthopedics unit to Apollo for $20 billion, which could lead to a loss of a major revenue stream and strategic focus, potentially impacting the company’s MedTech segment performance and long-term growth trajectory.
-
The company’s valuation, with a P/E ratio of 30.92, is relatively high compared to historical averages, which may limit upside potential if growth expectations are not met, particularly given the challenges in the neuroscience and immunology segments.
| | View Today's Stock Pick |
|
